Overview

A Study of Vedolizumab in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Status:
Not yet recruiting
Trial end date:
2030-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the long-term vedolizumab intravenous (IV) treatment is safe in pediatric participants with UC or CD. Participants will receive an injection of vedolizumab once every 8 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Vedolizumab